The Foundation for Angelman Syndrome Therapeutics (FAST) has awarded a 2-year grant to Frances Arnold, PhD, winner of the 2018 Nobel Prize in Chemistry, to develop new molecular tools that could help advance future RNA-targeted therapeutics for Angelman syndrome.